Recent Finacing
Recent Raise
Progentos develops small-molecule therapeutics that induce endogenous oligodendrocyte progenitor cells to remyelinate axons in demyelinating diseases such as multiple sclerosis, with in vivo regeneration and planned human proof-of-concept studies.
